This website uses technical, customisation and analytical cookies, both first-party and third-party, to anonymously facilitate browsing and analyse statistics on use of the website. Learn more
Search results
-
Kaspi.kz IPO
Ivashina, Victoria; Cekin, EselCase HBS-220007-EFinanceThis case follows Kaspi.kz, a private equity (Baring Vostok) co-owned retail bank in Central Asia that evolved into a fintech, payments and e-commerce company. It provides insights into private equity financing, portfolio company management, and initial public offering practices. In particular, the case focuses on (i) the bank's journey from a traditional bank that serviced only corporations to an online platform, and (ii) the timing and process ...Starting at €8.20
-
TPG China: Daphne International
Ivashina, VictoriaCase HBS-813055-EFinanceTo maximize their effectiveness, color cases should be printed in color.Starting at €8.20
-
Halftime for Heidelberg
Spar, Debora L.Case HBS-720021-EStrategyThe case follows President Rob Huntington as he seeks to find a viable way forward for Heidelberg University. Located in Tiffin, Ohio, Heidelberg is a small, private, four-year university. As with many similar institutions of higher education, it currently faces a daunting and mounting set of challenges, most of which stem from financial and demographic changes that are far beyond its control. During Huntington's eleven-year tenure, the universi...Starting at €8.20
-
HCA, Inc. LBO Exit
Ivashina, VictoriaCase HBS-813056-EEntrepreneurshipThis case discusses the events following the 2006 $33.2 billion buyout of Hospital Corporation of America (HCA) by a consortium of private equity firms, including Bain Capital, KKR, and Merrill Lynch's private equity arm. The case highlights some of the core features of private equity investing. The first objective of the case is to allow students to understand a range of issues associated with the process of exit through an initial public offeri...Starting at €8.20
-
TowerBrook: ESG in Action (A)
Ivashina, Victoria; Trelstad, Brian; Conway, MeaghanCase HBS-221045-EFinancesome TowerBrook team members were excited about the company's growth potential, while others were concerned about the optics of its social impact. Overall, this case can be used to understand how private equity firms are integrating ESG considerations into their decision-making processes.Starting at €8.20
-
Granite Equity Partners, Teaching Note
Ivashina, Victoria; Shu, TerrenceTeaching Note HBS-820062-EFinanceThis teaching note accompanies HBS case 219040, "Granite Equity Partners," which follows the private equity firm as it evaluates the potential acquisition of Tyrell Corp., a Minnesota-based quality control biomaterials company. Granite Equity's fund was different from most other private equity funds in that it had a perpetual, or "evergreen," structure, meaning it invested in assets without a defined holding period. The case and teaching note des...Starting at €0.00
-
Afrigen Biologics: Vaccines for the Global South, Teaching Note
Spar, Debora L.; Comeau, JuliaTeaching Note HBS-323098-EEconomicsTeaching note to case 323030Starting at €0.00
-
The Social Purpose of the Firm
Spar, Debora L.; Comeau, JuliaCase HBS-323051-EKnowledge and CommunicationThe Social Purpose of the Firm (SPF) is a short module designed to explore how, and under what circumstances, business leaders can harness the power of capitalism and markets to "make a difference in the world" - that is, to address a significant societal problem as a commercial endeavor. This Module Note summarizes the cases and themes discussed in SPF. Together, the cases are designed to study entrepreneurs and business leaders who are tackling...Starting at €8.20
-
Extend Fertility: Conceiving the Market for Egg Preservation, Teaching Note
Spar, Debora L.; Hull, OliviaTeaching Note HBS-720002-EStrategyTeaching note for case 719019.Starting at €0.00
-
Afrigen Biologics: Vaccines for the Global South
Spar, Debora L.; Comeau, JuliaCase HBS-323030-EEconomicsThe majority of vaccines used on the continent of Africa (99%) are produced offshore. This makes African nations reliant on the West for major health care needs, a problem which was exacerbated by the COVID-19 pandemic. Afrigen Biologics (in partnership with the WHO) is seeking to lessen this disparity by putting vaccine production in the hands of South Africans and other low- and middle-income countries. Afrigen Biologics is the first in a plann...Starting at €8.20